title: The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
authors.affiliation: Institute for Safe Medication Practices, Alexandria, Virginia, USA.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Moore
authors.forename: Curt D
authors.initials: CD
authors.lastname: Furberg
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use; D018278:Carcinoma, Neuroendocrine; D002986:Clinical Trials as Topic; D000069604:Dabigatran; D017277:Drug Approval; D017598:Efficiency, Organizational; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy; D061214:Patient Safety; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D011409:Propylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use; D012306:Risk; D013110:Sphingosine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D020521:Stroke / Q000517:prevention & control; D013964:Thyroid Neoplasms / Q000188:drug therapy; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D007166:Immunosuppressive Agents; D010880:Piperidines; D011409:Propylene Glycols; D011799:Quinazolines; D015091:beta-Alanine; D000068876:Fingolimod Hydrochloride; D000069604:Dabigatran; D013110:Sphingosine; C452423:vandetanib